吲哚醌抗帕金森病药理作用研究进展  

The pharmacological effects of isatin on Parkinson′s disease

作　　者：胥建[1] 徐辉辉[2] 尹磊[1] 岳旺[3] 李晓玲[2] XU Jian;XU Hui-hui;YIN Lei;YUE Wang;LI Xiao-ling(The Affiliated Hosipital of Qingdao University,Qingdao Shandong 266012,China;Qingdao Municipal Hospital,Qingdao Shandong 266011,China;Qingdao university,Qingdao,Shandong 266071,China)

机构地区：[1]青岛大学附属医院,山东青岛266012 [2]青岛市市立医院,山东青岛266011 [3]青岛大学,山东青岛266071

出　　处：《中国药理学通报》2023年第10期1815-1818,共4页Chinese Pharmacological Bulletin

基　　金：科技部“重大新药创制”科技重大专项(No 2009ZX09102-050);国家自然科学基金资助项目(No 30070867)。

摘　　要：帕金森病(Parkinson′s disease,PD)是一种神经退行性病变,治疗药物主要有拟多巴胺药和抗胆碱药两大类,多巴胺类及其增效剂现有长足发展,包括单胺氧化酶-B(monoamine oxidase B,MAO-B)抑制剂、儿茶酚-氧位-甲基转移酶抑制剂、麦角类和非麦角类多巴胺(dopamine,DA)受体激动剂、DA前体药物,中药大麻类和吲哚醌等。吲哚醌作为内源特异抗老化酶MAO-B抑制剂,有多种药理活性,其机制还涉及多种蛋白调节的活性。Parkinson′s disease(PD)is a kind of senile neurodegenerative disease.Dopaminergic drugs and anticholinergic drugs are the two major therapeutic drugs for PD.In the past several decades,great progress has been achieved on dopamines(DAs)and their synergists including monoamine oxidase B(MAO-B)inhibitors,catechol oxygen methyltransferase inhibitors,ergot and nonergot DA receptor agonists,DA precursor drugs,cannabis and isatin.Isatin is the inhibitor of endogenous specific anti-aging enzyme MAO-B,which has a variety of pharmacological activities.Moreover,the pharmacological mechanism of isatin may be associated with the regulatory functions of various protein activities.

关 键 词：吲哚醌 帕金森病 蛋白活性调节剂 单胺氧化酶-B 多巴胺 胆碱 

分 类 号：R745.7[医药卫生—神经病学与精神病学] R971.1[医药卫生—临床医学] R971.92